The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for BioAtla Inc. (BCAB) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.02, or 0.54%, to $3.72. The BioAtla Inc. has recorded 14,482 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones.
BioAtla Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $3.70 and fluctuated between $4.1785 as its day high and $3.5900 as its day low. The current market capitalization of BioAtla Inc. is $175.53M. A total of 3.26 million shares were traded on the day, compared to an average of 670.61K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, BCAB has seen 1 BUY and 8 SELL insider trades, representing the acquisition of 2,000 and the disposition of 7,019 shares. Over the last 12 months, there were 6 BUYs and 48 SELLs from insiders. Insiders purchased 55,000 shares during that period but sold 51,382.
In the most recent transaction, MCBRINN SYLVIA bought 3,700 shares of BCAB for 8.33 per share on Dec 19. After the transaction, the Director now owns 9,125 company shares. In a previous transaction on Nov 22, MCBRINN SYLVIA bought 2,000 shares at 8.27 per share. BCAB shares that Director owns now total 5,425.
Among the insiders who bought shares, MCBRINN SYLVIA acquired of 1,000 shares on Sep 13 at a per-share price of $8.20. This resulted in the Director holding 3,000 shares of BCAB after the transaction. In another insider transaction, MCBRINN SYLVIA bought 2,000 shares at $8.85 per share on Sep 12. Company shares held by the Director now total 2,000.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for BCAB in the last 3 months, the mean price target is $26.14 with high estimates of $68.00 and low estimates of $8.00. In terms of 52-week highs and lows, BCAB has a high of $16.27 and a low of $2.01.
As of this writing, BCAB has an earnings estimate of -$0.7 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.45 per share and a lower estimate of -$0.87. The company reported an EPS of -$0.77 in the last quarter, which was -11.60% lower than expectations of -$0.69.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BCAB’s latest balance sheet shows that the firm has $244.98M in Cash & Short Term Investments as of fiscal 2021. There were $5.37M in debt and $19.81M in liabilities at the time. Its Book Value Per Share was $3.80, while its Total Shareholder’s Equity was $210.82M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 7 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BCAB is Overweight with a score of 5.00. A total of 6 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.